Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $428.40. The company's market cap stands at 108.83B, with a P/E ratio of 28.34.
As of 2026-04-07, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $425.26 and $435.50. The current price stands at $428.40, placing the stock +0.7% above today's low and -1.6% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 294.64K, compared to an average daily volume of 1.36M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $510.77 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $510.77 at its peak.
VRTX News
Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. T...
RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the share...
Key Points CRISPR Therapeutics is the second largest holding in Cathie Wood's Ark Innovation ETF. Incoming clinical trial data could send the stock soaring th...
Analyst ratings
78%
of 36 ratingsMore VRTX News
In early April 2026, Vertex Pharmaceuticals reported expanded U.S. FDA approvals for its cystic fibrosis therapies ALYFTREK and TRIKAFTA, and completed a rollin...
Vertex Pharmaceuticals received FDA approval to expand the use of ALYFTREK and TRIKAFTA to additional age groups and CFTR gene variants. The expanded labels ma...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.